{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:31:29Z","timestamp":1788535889199,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jtct.2023.01.009","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T21:28:41Z","timestamp":1673645321000},"page":"313.e1-313.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Impact of Post-Transplantation Cyclophosphamide on Transfusion Requirements in HLA-Matched Sibling Peripheral Blood Stem Cell Transplantation"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-229X","authenticated-orcid":false,"given":"Javier","family":"Marco-Ayala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0679-2905","authenticated-orcid":false,"given":"In\u00e9s","family":"G\u00f3mez-Segu\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1633-2918","authenticated-orcid":false,"given":"Aitana","family":"Balaguer-Rosello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Montoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Guerreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Chorao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Facal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Villalba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8354-768X","authenticated-orcid":false,"given":"Javier","family":"de la Rubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Solves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.01.009_bib0001","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.01.009_bib0002","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/bloodadvances.2020001648","article-title":"Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults","volume":"4","author":"Symons","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.01.009_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.605726","article-title":"GVHD prophylaxis 2020","volume":"12","author":"Gooptu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2023.01.009_bib0004","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.01.009_bib0005","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2014-07-587477","article-title":"Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS","volume":"124","author":"Kanakry","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.01.009_bib0006","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41409-020-0921-6","article-title":"Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors","volume":"55","author":"Montoro","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.01.009_bib0007","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-021-01094-2","article-title":"Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT","volume":"14","author":"Sanz","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2023.01.009_bib0008","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2023.01.009_bib0009","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.bbmt.2016.03.004","article-title":"Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil","volume":"22","author":"Moiseev","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.01.009_bib0010","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood.2019000487","article-title":"Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation","volume":"134","author":"Battipaglia","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.01.009_bib0011","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/bloodadvances.2019000236","article-title":"Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation","volume":"3","author":"Kwon","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.01.009_bib0012","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/bmt.2016.80","article-title":"Longer delay of hematological recovery and increased transfusion needs after haploidentical compared to non-haploidentical stem cell transplantation","volume":"51","author":"Desjonqueres","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.01.009_bib0013","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/trf.12817","article-title":"Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantation","volume":"55","author":"Christou","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.jtct.2023.01.009_bib0014","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/bmt.2016.42","article-title":"Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS","volume":"51","author":"de la Serna","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.01.009_bib0015","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1365-2141.2001.03153.x","article-title":"Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study","volume":"115","author":"Martino","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2023.01.009_bib0016","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1200\/JCO.2007.11.1641","article-title":"Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival","volume":"26","author":"Valc\u00e1rcel","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.01.009_bib0017","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jinf.2019.02.009","article-title":"Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: implications for the diagnosis of CMV pneumonia","volume":"78","author":"Pi\u00f1ana","year":"2019","journal-title":"J Infect"},{"key":"10.1016\/j.jtct.2023.01.009_bib0018","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.bbmt.2013.03.018","article-title":"Clinical guide to ABO-incompatible allogeneic stem cell transplantation","volume":"19","author":"Booth","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.01.009_bib0019","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.01.009_bib0020","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.01.009_bib0021","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.01.009_bib0022","first-page":"2","article-title":"ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients","volume":"73","author":"Cesaro","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jtct.2023.01.009_bib0023","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.01.009_bib0024","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/bmt.2015.305","article-title":"Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission","volume":"51","author":"Ruggeri","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.01.009_bib0025","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/aje\/kwq224","article-title":"Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score","volume":"172","author":"Austin","year":"2010","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jtct.2023.01.009_bib0026","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jtct.2023.01.009_bib0027","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.jtct.2023.01.009_bib0028","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.01.009_bib0029","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/trf.15961","article-title":"Red blood cell and platelet transfusion support in the first 30 and 100\u2009days after allogeneic hematopoietic cell transplant","volume":"60","author":"Yuan","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.jtct.2023.01.009_bib0030","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1016\/j.bbmt.2009.12.323","article-title":"The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative hematopoietic cell transplantation (HCT)","volume":"16","author":"Wang","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.01.009_bib0031","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/trf.14966","article-title":"Transfusion support for matched sibling allogeneic hematopoietic stem cell transplantation (1993-2010): factors that predict intensity and time to transfusion independence","volume":"59","author":"Griffith","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.jtct.2023.01.009_bib0032","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/ejh.13270","article-title":"Comparison of transfusion requirements in adult patients undergoing haploidentical or single-unit umbilical cord blood stem cell transplantation","volume":"103","author":"Solves","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtct.2023.01.009_bib0033","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.bbmt.2018.12.142","article-title":"Higher incidence of hemorrhagic cystitis following haploidentical related donor transplantation compared with matched related donor transplantation","volume":"25","author":"Copelan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.01.009_bib0034","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1016\/j.transproceed.2009.06.189","article-title":"Impact of ABO-incompatible donor on early and late outcome of hematopoietic stem cell transplantation","volume":"41","author":"Ozkurt","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jtct.2023.01.009_bib0035","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-018-0586-4","article-title":"Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT","volume":"11","author":"Ruggeri","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2023.01.009_bib0036","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41409-019-0547-8","article-title":"Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application","volume":"55","author":"el Fakih","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.01.009_bib0037","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/imj.12894","article-title":"Red cell and platelet transfusion burden following myeloablative allogeneic haemopoietic stem cell transplantation","volume":"45","author":"Le Viellez","year":"2015","journal-title":"Intern Med J"},{"key":"10.1016\/j.jtct.2023.01.009_bib0038","first-page":"373","article-title":"RBC transfusion requirements after allogeneic marrow transplantation: impact of the before-transplant Hb level on transfusion and early survival","volume":"43","author":"Xenocostas","year":"2003"},{"key":"10.1016\/j.jtct.2023.01.009_bib0039","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41409-019-0555-8","article-title":"Red blood cell transfusion burden by day 30 predicts mortality in adults after single-unit cord blood transplantation","volume":"54","author":"Konuma","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.01.009_bib0040","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/trf.12396","article-title":"The association between red blood cell and platelet transfusion and subsequently developing idiopathic pneumonia syndrome after hematopoietic stem cell transplantation","volume":"54","author":"Vande Vusse","year":"2014","journal-title":"Transfusion"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723000337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723000337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:09:41Z","timestamp":1763003381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723000337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2666636723000337"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.01.009","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Post-Transplantation Cyclophosphamide on Transfusion Requirements in HLA-Matched Sibling Peripheral Blood Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}